What’s new

• Management revised its API plant funding story, now saying ₹25-30 cr more is needed for clean-room facilities.
• FY27 revenue target is ₹274 cr, aiming to bounce back from a ₹24.66 cr net loss in FY26.
• A 68% combined US tariff on HPMC capsules is a major headwind for exports.

Why it matters

The revised capex need contradicts earlier statements that the plant was fully capitalized. For a loss-making nano-cap, finding an extra ₹25-30 cr while debt is set to rise toward ₹110 cr is a real funding question. Management's credibility on hitting targets is already dented by a significant miss on prior API sales guidance.

What we’re watching

• Where the ₹25-30 cr in new capex will come from, given rising debt and thin cash.
• Progress on regulatory approvals for the five simultaneous expansions.
• Whether the FY27 ₹274 cr revenue target survives the US tariff hit.

The full read

Natural Capsules guided ₹274 crore in revenue for FY27, aiming to reverse a ₹24.66 crore net loss. But the call exposed a funding wrinkle: the steroidal API plant now needs an extra ₹25-30 crore for clean-room facilities. That's a change from earlier claims the plant was fully capitalized. The timing is awkward. Debt is projected to climb to ₹100-110 crore through FY28 as the company pursues five expansions at once. Exports face a 68% combined US tariff on HPMC capsules, and management skipped specific margin guidance. The prior API sales target was already missed significantly. For a loss-making nano-cap, the open question is how it funds the extra capex without further straining the balance sheet.

Primary source: BSE · NSE